公开(公告)号：US20200165584A1

公开(公告)日：2020-05-28

申请号：US16593750

申请日：2019-10-04

Applicant: VEGENICS PTY LIMITED

Inventor： Michael Gerometta ,  Timothy Adams

IPC: C12N9/12 ,  C07K16/00 ,  A61K39/395 ,  A61K38/45 ,  A61K45/06 ,  A61K47/64 ,  C07K14/71

Abstract: The present invention is directed to ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis.

公开(公告)号：US20160002612A1

公开(公告)日：2016-01-07

申请号：US14768701

申请日：2014-02-13

Applicant: VEGENICS PTY LIMITED

Inventor： Michael Gerometta ,  Timothy Adams

IPC: C12N9/12 ,  A61K39/395 ,  A61K38/45 ,  A61K45/06 ,  C07K16/00

CPC classification number: C12N9/12 ,  A61K38/00 ,  A61K38/45 ,  A61K39/395 ,  A61K45/06 ,  A61K47/64 ,  C07K14/71 ,  C07K16/00 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/70 ,  C12N2710/10043 ,  C12Y207/10001

Abstract: The present invention is directed to ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis.

Abstract translation: 本发明涉及配体结合分子及其用于调节血管生成和/或淋巴管生成的用途。

公开(公告)号：US20240301370A1

公开(公告)日：2024-09-12

申请号：US18523811

申请日：2023-11-29

Applicant: VEGENICS PTY LIMITED

Inventor： Michael Gerometta ,  Timothy Adams

IPC: C12N9/12 ,  A61K38/00 ,  A61K38/45 ,  A61K39/395 ,  A61K45/06 ,  A61K47/64 ,  C07K14/71 ,  C07K16/00

CPC classification number: C12N9/12 ,  A61K38/45 ,  A61K39/395 ,  A61K45/06 ,  A61K47/64 ,  C07K14/71 ,  C07K16/00 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/70 ,  C12N2710/10043 ,  C12Y207/10001

Abstract: The present invention is directed to ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis.

公开(公告)号：US11866739B2

公开(公告)日：2024-01-09

申请号：US16593750

申请日：2019-10-04

Applicant: VEGENICS PTY LIMITED

Inventor： Michael Gerometta ,  Timothy Adams

IPC: C12N9/12 ,  C07K14/71 ,  A61K47/64 ,  A61K45/06 ,  A61K38/45 ,  A61K39/395 ,  C07K16/00 ,  A61K38/00

CPC classification number: C12N9/12 ,  A61K38/45 ,  A61K39/395 ,  A61K45/06 ,  A61K47/64 ,  C07K14/71 ,  C07K16/00 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/70 ,  C12N2710/10043 ,  C12Y207/10001

Abstract: The present invention is directed to ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis.

公开(公告)号：US09745558B2

公开(公告)日：2017-08-29

申请号：US14768701

申请日：2014-02-13

Applicant: VEGENICS PTY LIMITED

Inventor： Michael Gerometta ,  Timothy Adams

IPC: A61K38/17 ,  C07K14/435 ,  C12N9/12 ,  A61K45/06 ,  A61K47/48 ,  C07K14/71 ,  A61K38/45 ,  A61K39/395 ,  C07K16/00 ,  A61K38/00

CPC classification number: C12N9/12 ,  A61K38/00 ,  A61K38/45 ,  A61K39/395 ,  A61K45/06 ,  A61K47/64 ,  C07K14/71 ,  C07K16/00 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/70 ,  C12N2710/10043 ,  C12Y207/10001

Abstract: The present invention is directed to VEGFR-3 ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis. A glycosylation sequon of wildtype VEGFR-3 has been modified to eliminate glycosylation in the ligand binding molecules.